Based on the Iterum Therapeutics PLC stock forecast from 0 analysts, the average analyst target price for Iterum Therapeutics PLC is not available over the next 12 months. Iterum Therapeutics PLC’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Iterum Therapeutics PLC is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Iterum Therapeutics PLC’s stock price was USD 1.12. Iterum Therapeutics PLC’s stock price has changed by +0.90% over the past week, -18.84% over the past month and -28.66% over the last year.
No recent analyst target price found for Iterum Therapeutics PLC
No recent average analyst rating found for Iterum Therapeutics PLC
Company Overview Iterum Therapeutics PLC
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Read Less
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract inf...Read More
Frequently Asked Questions About Iterum Therapeutics PLC (ITRM) Stock
Stock Target Advisor's fundamental analysis for Iterum Therapeutics PLC's stock is Bearish.
Unfortunately we do not have enough data on ITRM's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ITRM's stock to indicate what its average analyst target is.
ITRM stock's Price/Earning ratio is 9.31.
Our analysis grades ITRM stock's Price / Earning ratio at F. This means that ITRM stock's Price/Earning ratio is above 56.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ITRM may be a overvalued for its sector.
The last closing price of ITRM's stock was USD 1.12.
The most recent market capitalization for ITRM is USD 0.04B.
Unfortunately we do not have enough analyst data on ITRM's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Iterum Therapeutics PLC's stock.
As per our most recent records Iterum Therapeutics PLC has 9 Employees.
Iterum Therapeutics PLC's registered address is 3 Dublin Landings, Dublin, Ireland, D01 C4E0.
You can get more information about it from Iterum Therapeutics PLC's website at https://www.iterumtx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Iterum Therapeutics PLC (ITRM) Stock
Stock Target Advisor's fundamental analysis for Iterum Therapeutics PLC's stock is Bearish.
Unfortunately we do not have enough data on ITRM's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ITRM's stock to indicate what its average analyst target is.
ITRM stock's Price/Earning ratio is 9.31.
Our analysis grades ITRM stock's Price / Earning ratio at F. This means that ITRM stock's Price/Earning ratio is above 56.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ITRM may be a overvalued for its sector.
The last closing price of ITRM's stock was USD 1.12.
The most recent market capitalization for ITRM is USD 0.04B.
Unfortunately we do not have enough analyst data on ITRM's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Iterum Therapeutics PLC's stock.
As per our most recent records Iterum Therapeutics PLC has 9 Employees.
Iterum Therapeutics PLC's registered address is 3 Dublin Landings, Dublin, Ireland, D01 C4E0.
You can get more information about it from Iterum Therapeutics PLC's website at https://www.iterumtx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ITRM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
